Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dextrose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.48 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | PYGB | P11216 | 7/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beta-D-Glucose SCHEMBL361597 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL361799 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL16429773 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Dextrose SCHEMBL7651668 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| D-Mannose SCHEMBL1772795 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| D-Galactose SCHEMBL17593535 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL361340 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL361515 | 1.00 | LGALS1 (0.48) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL9847381 | 0.98 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Ribose (Furanose) SCHEMBL27896040 | 0.98 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101610798-A | Drug releasing coatings for medical devices | LUTONIX INC (US) | 2009-12-23 | — | — | CN | claimed |
| US-20230165840-A1 | TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH ANTI-PROLIFERATE AND ANTI-INFLAMMATORY DRUGS | LUTONIX, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-11534430-B2 | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs | LUTONIX, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| CN-109328297-A | Container assemblies and the preparation method of sample for using the container assemblies | 株式会社岛津制作所 | 2019-02-12 | — | — | CN | disclosed |
| EP-3191598-A1 | PROCESS FOR THE ENZYMATIC PREPARATION OF A PRODUCT GLUCOSIDE AND OF A CO-PRODUCT FROM AN EDUCT GLUCOSIDE | Pfeifer & Langen GmbH & Co. KG (DE) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016038142-A1 | PROCESS FOR THE ENZYMATIC PREPARATION OF A PRODUCT GLUCOSIDE AND OF A CO-PRODUCT FROM AN EDUCT GLUCOSIDE | Pfeifer & Langen GmbH & Co. KG (DE) | 2016-03-17 | — | — | WO | disclosed |
| CN-101610798-B | Drug releasing coatings for medical devices | LUTONIX INC | 2013-07-17 | — | — | CN | disclosed |
| CN-101610798-A | Drug releasing coatings for medical devices | LUTONIX INC (US) | 2009-12-23 | — | — | CN | disclosed |
| US-7102023-B2 | Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040220389-A1 | Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220389-A1 | Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries | FUT5, FUT6, UGCG | LGALS1 87/4885LGALS3 53/4885LGALS9 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.